Recurrent Cervical Cancer
Current Clinical Trials
No standard treatment is available for patients with recurrent cervical cancer that has spread
beyond the confines of a radiation or surgical field. For locally recurrent disease, pelvic exenteration can lead
to a 5-year survival rate of 32% to 62% in selected patients.[1,2] These patients are
appropriate candidates for clinical trials testing drug combinations or new
anticancer agents.
Treatment options:
- For recurrence in the pelvis following radical surgery, radiation therapy in
combination with chemotherapy (fluorouracil with or without mitomycin) may cure
40% to 50% of patients.[3]
- Chemotherapy can be used for palliation. Tested drugs include:
- Cisplatin (15%–25% response rate).[4]
- Ifosfamide (15%–30% response rate).[5,6]
- Ifosfamide-cisplatin.[7,8]
- Paclitaxel (17% response rate).[9]
- Irinotecan (21% response rate in patients previously treated with
chemotherapy).[10]
- Paclitaxel/cisplatin (46% response rate).[11]
- Cisplatin/gemcitabine (41% response rate).[12]
Current Clinical Trials
Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with recurrent cervical cancer. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.
General information about clinical trials is also available from the NCI Web site.
References
-
Alberts DS, Kronmal R, Baker LH, et al.: Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group Study. J Clin Oncol 5 (11): 1791-5, 1987.
[PUBMED Abstract]
-
Tumors of the cervix. In: Morrow CP, Curtin JP: Synopsis of Gynecologic Oncology. 5th ed. New York, NY: Churchill Livingstone, 1998, pp 107-151.
-
Thomas GM, Dembo AJ, Black B, et al.: Concurrent radiation and chemotherapy for carcinoma of the cervix recurrent after radical surgery. Gynecol Oncol 27 (3): 254-63, 1987.
[PUBMED Abstract]
-
Thigpen JT, Blessing JA, DiSaia PJ, et al.: A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 32 (2): 198-202, 1989.
[PUBMED Abstract]
-
Coleman RE, Harper PG, Gallagher C, et al.: A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix. Cancer Chemother Pharmacol 18 (3): 280-3, 1986.
[PUBMED Abstract]
-
Sutton GP, Blessing JA, McGuire WP, et al.: Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study. Am J Obstet Gynecol 168 (3 Pt 1): 805-7, 1993.
[PUBMED Abstract]
-
Buxton EJ, Meanwell CA, Hilton C, et al.: Combination bleomycin, ifosfamide, and cisplatin chemotherapy in cervical cancer. J Natl Cancer Inst 81 (5): 359-61, 1989.
[PUBMED Abstract]
-
Omura GA, Blessing JA, Vaccarello L, et al.: Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 15 (1): 165-71, 1997.
[PUBMED Abstract]
-
McGuire WP, Blessing JA, Moore D, et al.: Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol 14 (3): 792-5, 1996.
[PUBMED Abstract]
-
Verschraegen CF, Levy T, Kudelka AP, et al.: Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 15 (2): 625-31, 1997.
[PUBMED Abstract]
-
Rose PG, Blessing JA, Gershenson DM, et al.: Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 17 (9): 2676-80, 1999.
[PUBMED Abstract]
-
Burnett AF, Roman LD, Garcia AA, et al.: A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix. Gynecol Oncol 76 (1): 63-6, 2000.
[PUBMED Abstract]
Back to Top
< Previous Section | Next Section > |